Note 15 - Segment and Geographic Information

3 Months Ended

Aug. 31, 2013

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

15.    SEGMENT AND GEOGRAPHIC INFORMATION

Through February 2013, the Company was organized by geographic area and reported three operating segments: United States (“U.S.”), Europe and Other. In March 2013, after the acquisition of the LIFECODES business, the Company reorganized its operating structure, and reevaluated its reportable operating segments accordingly. The Company determines operating segments in accordance with its internal operating structure, which is organized based upon product groups. Each segment is separately managed and is evaluated primarily upon operating results. The Company has two operating segments, the Transfusion segment and the Transplant & Molecular segment, which have been aggregated into one reportable segment. The financial information provided below has been recast to reflect the Company’s new segment structure for each period presented.

The Company manufactures and markets a complete line of diagnostics products and automated systems used primarily by hospitals, donor centers and reference laboratories in a number of tests performed to detect and identify certain properties of human blood and human tissue to ensure the most compatible match between patient and donor. These tests are performed for the purpose of blood transfusion, pre-transplant human leukocyte antigen (HLA) typing and screening processes as well as post-transplant patient monitoring to aid in the identification of graft rejection.

The Company operates in various geographies. These geographic markets are comprised of the United States, Europe, Canada and other international markets. Major international markets include Japan, Brazil, Russia, India, China, Turkey, the Middle East and Africa. The Company’s products are marketed globally, both directly to the end user and through established distributors.

Accounting policies for segments are the same as those described in the summary of significant accounting policies.

The following is a summary of the Company’s segment data (in thousands):

	Three Months Ended
	August 31
	2013		2012
Net sales by product group:
Transfusion	$	82,990		83,570
Transplant & Molecular		13,054		1,584
Total	$	96,044		85,154

Following is a summary of enterprise-wide information (in thousands):

	Three Months Ended
	August 31
	2013		2012
Net sales to customers by geography are as follows:
United States	$	61,120		57,825
Europe (A)		17,851		14,869
Canada		4,553		5,078
Other		12,520		7,382
Total	$	96,044		85,154

Net sales are attributed to individual countries based on the customer’s country of origin at the time of the sale and where the Company has an operating entity.

	As of
	August 31, 2013		May 31, 2013
Long-lived tangible assets by geography:
United States	$	55,171		57,184
Europe (B)		14,152		13,399
Canada		4,446		4,511
Other (C)		1,571		1,287
Total	$	75,340		76,381

	As of
	August 31, 2013		May 31, 2013
Concentration of net assets by geography:
United States	$	484,416		485,968
Europe		110,668		114,740
Canada		32,564		32,910
Other (C)		11,455		11,088
Total	$	639,103		644,706

(A) – Net sales to any individual country within Europe were not material to the Company’s consolidated net sales.

(B) - Long-lived assets located in any individual country within Europe were not material to the Company's consolidated long-lived assets.

(C) - Primarily Japan and India.

Sales to an individual customer did not exceed more than 10% of our net sales during the three months ended August 31, 2013, or August 31, 2012.